Another FGFR Inhibitor Active in Bile Duct Cancers

(MedPage Today) -- More than 40% of patients with advanced cholangiocarcinoma (CCA) had objective responses that were durable in most cases following treatment with a multitargeted fibroblast growth factor receptor (FGFR) inhibitor, a preliminary...